Bachelor's degree in biology, microbiology, biochemistry, biochemical engineering, or related field with 7+ years of GMP manufacturing experience, or a Master's/PhD with 5+ years and 2+ years in a leadership role.
Experience with Contract Development and Manufacturing Organizations (CDMOs) preferred.
Hands-on experience with microbial, mammalian, and/or oligonucleotide processes required.
Proficiency in AKTA chromatography/filtration operation and Unicorn software programming.
Strong understanding of current and novel purification technologies.
Responsibilities
Serve as the Downstream Processing (DSP) subject matter expert for recombinant protein development and commercialization.
Represent CMC and sub-teams on DSP process development within the Development Team.
Collaborate with CDMOs to develop compliant drug substance manufacturing processes at various scales.
Troubleshoot and resolve complex technical issues in recovery and purification processes.
Provide guidance on protein characterization and critical attributes for effective purification development.
Author technical reports and contribute to regulatory submissions.
Support CMC data packages for regulatory submissions and review meetings.
Benefits
Opportunity to work on cutting-edge recombinant protein technologies.
Collaborative environment with cross-functional teams.
Direct involvement in regulatory submission processes.
Leadership opportunities in managing technical projects.
Access to professional development and training resources.
Full Job Description
Job Description
Detailed Responsibilities:
Technical Scope
Serve as Downstream Processing (DSP) subject matter expert in the development and commercialization of recombinant proteins that utilize clarification, chromatography, and filtration technologies.
As a contact on the Development Team, representing CMC and associated sub-teams on DSP process development work effort
Partner with CDMOs to develop drug substance manufacturing DSP processes and deliver drug substance at lab, pilot, and commercial scales in a phase appropriate and compliant manner
Proactively troubleshoots and mitigates complex technical issues associated with recovery and purification process development
Provides expertise, guidance, and direction on protein characterization and critical attributes so as to direct effective purification development and product/process control strategies
Authors technical development detailed reports and provides input/data for regulatory submissions
Provides direct technical support to CMC data package for regulatory submission(s) as well as IND, and/or BLA regulatory review meetings
Leadership Scope
Assembles and delivers CMC supporting regulatory documentation required to rationalize process controls, key indicators, and/or specifications
Collaborates effectively to achieve results as an individual as well as through others
With minimal supervision, generates and delivers concise/clear technical presentations to senior management
Generates and manages comprehensive budget and timelines for program project activities
Ensures product development team, individual, team, and organizational goals are achieved
Specialized Knowledge
Experience in Product recovery/clarification, chromatography, filtration, PAT, and/or high throughput screening (HTS) technologies
Experience in AKTA chromatography/filtration operation (and programming using Unicorn software)
Scientific understanding of current purification technologies, as well as the ability to explore and develop novel approaches to further advance innovative purification technologies
Qualifications:
Requires a bachelor's degree in biology, microbiology, biochemistry, biochemical engineering or a related field, with 7+ years of experience in GMP manufacturing or advanced degree (Master's or PhD) in biology, microbiology, biochemistry, biochemical engineering or a related field, with 5+ years of experience in GMP manufacturing with 2+ years of leadership experience managing technical, manufacturing and/or supply chain.
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company's second-generation MIGS device, the iStent inject, was approved by the FDA in June 2018. Glaukos is also developing a pipeline of innovative technologies in corneal health, including the recently acquired Microline surgical platform, as well as novel drug delivery technologies.